Cannabinoid based therapeutic - Tetra Pharm Technologies
Alternative Names: XATEPALatest Information Update: 28 Apr 2024
At a glance
- Originator Tetra Pharm Technologies
- Class Analgesics
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pain
Most Recent Events
- 19 Mar 2024 Tetra Pharm Technologies announces intention to launch cannabinoid based therapeutic in European and overseas markets in 2024
- 19 Mar 2024 Tetra Pharm Technologies and 4C LABS enters into distribution agreement for cannabinoid based therapeutic in the UK
- 19 Mar 2024 Tetra Pharm Technologies announces intention to launch cannabinoid based therapeutic in the UK in the second quarter of 2024